Belzutifan treatment for von hippel-lindau disease
Part of Brain & nervous system, Genetic & congenital, Heart & circulation clinical trials.
This study gathers information from people with a rare condition called VHL (a genetic disorder that increases the risk of certain tumors) who are taking the drug belzutifan. It looks at how well the drug works and how safe it is over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of VHL disease (through clinical or genetic testing).
- You must be using (or planning to use) belzutifan as part of your treatment.
- You must not have a tumor that needs immediate surgery.
- If you can get pregnant, you must not be pregnant and must agree to use contraception.
- You must not have serious, uncontrolled health issues like active infections or severe heart/lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special imaging agent that targets a protein found in tumors related to Von Hippel-Lindau (VHL) disease. It may help doctors better detect and monitor these tumors.
This trial tests the drug belzutifan (a pill taken by mouth) in people with VHL syndrome who have kidney or other VHL-related tumors that are growing or can be measured. The study looks at how well belzutifan works in real-world conditions and whether certain genetic factors affect how the drug works.
This Phase 2 study tests belzutifan (MK-6482) to treat certain advanced cancers caused by specific gene or disease changes, including VHL-related tumors and HIF-2α related tumors. It may help shrink tumors or slow their growth in people whose cancer matches these genetic or disease patterns.
This study is for people who are already taking belzutifan in a related trial (LITESPARK-043) and want to continue treatment for advanced solid tumors or von Hippel-Lindau-related conditions. It tests the safety and effects of long-term use.
This study tests an oral drug called belzutifan in teenagers with certain solid tumors. Belzutifan may shrink tumors by blocking a protein that helps them grow.
This study is for people with von Hippel-Lindau (vHL) disease to collect information for research. It may help researchers better understand the condition and how to care for people with it.
Hear when a new VHL - Von Hippel-Lindau Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.